

NTM Identification & Drug Resistance Testing

PCR with detection of amplicons by MALDI-TOF Mass Spectrometry



Nontuberculous mycobacteria (NTM) prevalence continues to increase worldwide, especially among senior and immunocompromised populations. Precise identification of NTM species – and in some cases subspecies – is crucial to not only determine the most effective treatment, but also to help identify re-exposure to highly similar organisms.

Our Expertise

National Jewish Health Advanced Diagnostic Laboratories is recognized internationally as a leading diagnostic laboratory for TB, NTM and other acid-fast organisms.


- CAP, CLIA and CAP15189SM accredited
- Full speciation and subspeciation of TB and NTM
- Comprehensive menu of susceptibility testing, including drugs not commonly tested elsewhere

New NTM Identification & Drug Resistance Methodology

Our Mycobacteriology Laboratory has developed a novel platform for identifying the most important NTM species and subspecies, as well as drug markers, using MALDI-TOF mass spectrometry on PCR amplicons generated for detection of each target. This lab-developed test is validated and has greater than 97% agreement with gold standard methods of identification.

The new PCR-based methodology will be the primary method utilized for identification and drug resistance testing of NTM samples. Samples will be automatically reflexed to additional appropriate methods such as sequencing or other line probe assays for a full and accurate identification.

Sensitivity & Specificity



ORDERING NTM TESTING

To order NTM testing from Advanced Diagnostic Laboratories please visit our test directory at **njlabs.org** or contact our client services team at **clinreflabs@njhealth.org** or **800.550.6227**.